Hikma Pharmaceuticals


Taking on-board near-term headwinds

10/01/22 -"Considering the ‘again’ worsening pandemic situation – due to the Omicron variant - a ‘complete’ recovery in elective surgeries, the principal driver for Hikma’s injectables segment (c.42% of sales), ..."

Pages
61
Language
English
Published on
10/01/22
You may also be interested by these reports :
17/01/22
GSK has rejected Unilever’s £50bn bid for the former’s Consumer Healthcare business. The British UK giant believes that the offer significantly ...

17/01/22
Moreover, with the possible monetisation of Consumer Healthcare, the firm should have sizeable resources at its disposal to expedite ...

17/01/22
Investors’ fatigue is the usual summary view about Bayer’s (Buy, Germany) share price, five years down the road of the Monsanto acquisition. Value ...

12/01/22
Unlike Smaller Pharmas’ lackluster performance (up 16% since the March 2020 lows vs. 73% gain for STOXX600) since the COVID-19 outbreak, Hikma (Buy, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO